Desmoid tumor research received well-deserved attention at the 2023 American Society of Clinical Oncologists (ASCO) annual conference. Data supporting the efficacy of nirogacestat were the focus of several presentations at the this year’s event. SpringWorks Therapeutics’ New Drug Application for nirogacestat is currently under review by the FDA.
In an interview with OncLive, Bernd Kasper, MD, PhD, Mannheim University Medical Center, University of Heidelberg, Germany, discusses the effect of nirogacestat on tumor volume and T2 hyperintensity in patients with desmoid tumors. | WATCH
OncLive also published an article titled, “Nirogacestat Provides Rapid and Sustained Pain Reduction for Patients With Desmoid Tumors,” summarizing the poster presentation by Winette T.A. Van Der Graaf, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands, et. al. | READ
Desmoid tumors were the subject of several poster presentations and discussion during the Sarcoma Track of ASCO 2023, on Saturday, June 3rd.
Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors
Thierry Alcindor, MD, MSc, McGill University Health Center, et. al.
Abstract: https://meetings.asco.org/abstracts-presentations/218369
Poster: https://dtrf.org/wp-content/uploads/2023/10/Alcindor_DeFi-Tumor-Volume-_-T2_2023-ASCO_Poster_FINAL.pdf
Poster supplement: https://dtrf.org/wp-content/uploads/2023/10/Alcindor_DeFi-Tumor-Volume-_-T2_2023-ASCO_Supplemental.pdf
Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study
Winette T.A. Van Der Graaf, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands, et. al.
Abstract: https://meetings.asco.org/abstracts-presentations/220655
Poster: https://dtrf.org/wp-content/uploads/2023/10/van-der-Graaf_DeFi-Pain_2023-ASCO_Poster_FINAL.pdf
RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results
Mrinal M. Gounder, MD, Memorial Sloan Kettering Cancer Center, et. al.
Abstract: https://meetings.asco.org/abstracts-presentations/218382
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27)
Young Kwang Chae, Northwestern University, Chicago, IL, et. al.
Abstract: https://meetings.asco.org/abstracts-presentations/220010
Impact of pregnancy in women with desmoid fibromatosis: An international retrospective observational study
Marco Fiore, MD, FACS, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, et. al.
Abstract: https://meetings.asco.org/abstracts-presentations/218386
Famitinib for familial adenomatous polyposis-associated aggressive desmoid tumors: A single-center exploratory study
Sai Ge, Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China, et. al.
Abstract: https://meetings.asco.org/abstracts-presentations/218434
